Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 4 institutions in 3 countries.
Andreas S KalogirouDepartment of Life Sciences, School of Sciences, European University Cyprus, 6 Diogenis Str., Engomi, P.O. Box 22006, Nicosia 1516, Cyprus.ORCID 0000-0002-5476-5805
Michael P EastDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Tuomo LaitinenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0003-1539-2142
Chad D TorriceDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Kaitlyn A MaffuidDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
David H DrewryStructural Genomics Consortium, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5973-5798
Panayiotis A KoutentisDepartment of Chemistry, University of Cyprus, P.O. Box 20537, Nicosia 1678, Cyprus.ORCID 0000-0002-4652-7567
Gary L JohnsonDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Daniel J CronaDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3742-8863
Christopher R M AsquithDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5871-3458
University of North Carolina at Chapel Hill · USEuropean University Cyprus · CYUniversity of Cyprus · CYUniversity of Eastern Finland · FI
Funding
Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
Cyprus Research Promotion Foundation NEAYPODOMH/NEKYP/0308/02NIDDK NIH HHS U24 DK116204Wellcome Trust
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors. · full record | OpenQuestion